UPC APP 8340/2025

—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Sonstige prozessuale
Parteien: Kläger
Alexion Pharmaceuticals, Inc.
Vertreter: Elena Hennecke (Freshfields)
Beklagte
Samsung Bioepis NL B.V.
Vertreter: Peter Meyer (Simmons & Simmons)
Division: Court of Appeal
Richter: Rian Kalden · Presiding judge and judge-rapporteur
Patricia Rombach · Legally qualified judge
Ingeborg Simonsson · Legally qualified judge
Technology: Organic Chemistry
Sprache: —
Erste Entscheidung: 19. Juni 2025

Entscheidungen

2025-06-19
AbgewiesenBerufungsentscheidungGeneric application
Court of Appeal Panel 2 rejected Alexion Pharmaceuticals' application for rehearing (R. 245 RoP) of the earlier Court of Appeal order dismissing Alexion's appeal against the Hamburg Local Division's denial of provisional measures. Alexion had alleged fundamental procedural defects (new claim interpretation standard applied without being heard, and incorrect facts). The Court held that no fundamental procedural defect within the meaning of Art. 81(1)(b) UPCA / R. 247(c) RoP was established. Alexion ordered to bear Samsung's costs of the rehearing proceedings.
Rechtsfragen:Rehearing application (Art. 81(1)(b) UPCA, R. 245 RoP)Fundamental procedural defectRight to be heard (Art. 76 UPCA)Paroxysmal nocturnal hemoglobinuria treatment / complement inhibitor

Dokumente